Not applicable.
No other company has an approved formulation of bis for clinical use.
The CoH deal was because CoH attempted to patent bis as a FTO inhibitor. The patent examiner rejected their claim. But CoH could have pursued this matter in the Courts. Rather than incur legal costs and put up with uncertainty for years, RAC decided to give CoH a small royalty and settle the dispute.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
-0.050(3.75%) |
Mkt cap ! $223.2M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $125.2K | 96.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21173 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 6431 | 2 |
View Market Depth
| Last trade - 15.34pm 23/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |